Research Blog
The prostate cancer research team I lead at Southampton has been having fantastic success in recent years. We have been contributing to trials that are really making a difference.
A novel, non-invasive test enabling bladder cancer detection in urine sediment of patients – European Urology Oncology 2019
Bladder cancer is the sixth most commonly diagnosed cancer in the European Union. Here, we evaluate the performance of a novel, commercially available enzyme-linked immunosorbent assay utilising MCM5 antibodies (ADXBLADDER; Arquer Diagnostics Ltd, Sunderland, UK) for...
Salvage cancer treatment after prostate radiotherapy – FORECAST Study
The FORECAST study has been assessing men with recurrent prostate cancer after prior radiotherapy. The study looked at the diagnosis / staging process to see whether a combination of MRI, PET-CT, Whole Body MRI and Bone scan could improve the detection of metastatic...
High Intensity Focused Ultrasound Research – INDEX study
The INDEX study has now completed recruitment. Its a landmark study in the making with the largest series of focal prostate HIFU treatments ever studied. Men with cancer on one side of the prostate who elected to have focal prostate HIFU have been studied and results...
ADXBLADDER and ADXPROSTATE urinary cancer tests
During my time as a Lecturer at UCL researching cancer markers I investigated the role of the cell-cycle protein Mcm5 in the field of urological cancer diagnosis. Since then the technology has been commercialised by Arquer diagnostics Ltd and I have led trials in both...